Literature DB >> 22915487

The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model.

M von Wilmsdorff1, M L Bouvier, U Henning, A Schmitt, T Schneider-Axmann, W Gaebel.   

Abstract

INTRODUCTION: An increased risk for metabolic syndrome has been described for patients with psychotic disorders. Antipsychotic drugs possibly contribute to metabolic changes.
METHODS: Haloperidol or clozapine was orally fed to male and female Sprague Dawley rats for 12 weeks, and body weight gain, food and water intake were measured. The serum levels of fasting glucose, HbA1c, triglycerides, cholesterol, HDL and LDL, insulin, leptin, adiponectin and ghrelin were determined. Gonadal and perirenal fat pads were removed and weighed.
RESULTS: We found increased body weight in the male clozapine group, but decreased ones in the male haloperidol group. Clozapine-treated male and female animals had higher fasting glucose, adiponectin, leptin, ghrelin, cholesterol, HDL and LDL levels, whereas haloperidol caused increased levels of insulin and decreased values of HbA1c, cholesterol, HDL and LDL.
CONCLUSION: Both antipsychotic drugs cause sex-dependent metabolic changes, which are risk factors for the metabolic syndrome, be it hyperinsulinemia under haloperidol treatment or hyperglycemia, hyperleptinemia and hyperlipidemia under clozapine. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915487     DOI: 10.1055/s-0032-1321907

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

1.  Effects of haloperidol and clozapine on synapse-related gene expression in specific brain regions of male rats.

Authors:  Martina von Wilmsdorff; Fabian Manthey; Marie-Luise Bouvier; Oliver Staehlin; Peter Falkai; Eva Meisenzahl-Lechner; Andrea Schmitt; Peter J Gebicke-Haerter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-05       Impact factor: 5.270

2.  Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.

Authors:  Fausto A Varela; Taleen Der-Ghazarian; Ryan J Lee; Sergios Charntikov; Cynthia A Crawford; Sanders A McDougall
Journal:  J Psychopharmacol       Date:  2013-09-17       Impact factor: 4.153

Review 3.  Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.

Authors:  Jiezhong Chen; Xu-Feng Huang; Renfu Shao; Chen Chen; Chao Deng
Journal:  Front Neurosci       Date:  2017-11-21       Impact factor: 4.677

4.  Sex-dependent alterations of dopamine receptor and glucose transporter density in rat hypothalamus under long-term clozapine and haloperidol medication.

Authors:  Marie-Luise Bouvier; Karin Fehsel; Andrea Schmitt; Eva Meisenzahl-Lechner; Wolfgang Gaebel; Martina von Wilmsdorff
Journal:  Brain Behav       Date:  2020-06-11       Impact factor: 2.708

Review 5.  The Role of Adiponectin in the Pathogenesis of Metabolic Disturbances in Patients With Schizophrenia.

Authors:  Cynthia Yi-An Chen; Kah Kheng Goh; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Front Psychiatry       Date:  2021-01-20       Impact factor: 4.157

6.  Sex-dependent effects of long-term clozapine or haloperidol medication on red blood cells and liver iron metabolism in Sprague Dawley rats as a model of metabolic syndrome.

Authors:  Marie-Luise Bouvier; Karin Fehsel; Andrea Schmitt; Eva Meisenzahl-Lechner; Wolfgang Gaebel; Martina von Wilmsdorff
Journal:  BMC Pharmacol Toxicol       Date:  2022-01-15       Impact factor: 2.483

7.  Cyclic AMP and calcium signaling are involved in antipsychotic-induced diabetogenic effects in isolated pancreatic β cells of CD1 mice.

Authors:  Ayat Al-Ghafari; Ekramy Mahmoud Elmorsy; Huda Al Doghaither; Eslam Fahmy
Journal:  Int J Health Sci (Qassim)       Date:  2022 Sep-Oct

Review 8.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.